December 29, 2014 1:34 AM ET

Pharmaceuticals

Company Overview of Andrx Corporation

Company Overview

Andrx Corporation, along with its subsidiaries, researches, develops, manufactures, commercializes, and distributes generic versions of controlled-release pharmaceuticals, oral contraceptives, and generic versions of immediate-release products. The company also develops and commercializes brand name pharmaceuticals; and distributes primarily generics that are commercialized by others and its own products. In addition, it offers contract services, such as development and manufacture of pharmaceutical products, including combination products and controlled-release formulations for other pharmaceutical companies; and contract research and development services. It sells generic products through ...

4955 Orange Drive

Davie, FL 33314

United States

Founded in 1992

1,680 Employees

Phone:

954-584-0300

Fax:

954-792-1034

Key Executives for Andrx Corporation

Chief Information Officer
Age: 63
Chief Operating Officer of Anda Inc. and Executive Vice President of Anda Inc
Age: 54
Chief Technical Officer of Andrx Pharmaceuticals Inc.
Age: 61
Professional
Executive Vice President of Commercial Development
Compensation as of Fiscal Year 2014.

Andrx Corporation Key Developments

Horizon Pharma, Inc. Files Suit in United States District Court for the District of New Jersey Against Watson Laboratories, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc

On August 26, 2013, Horizon Pharma, Inc. filed suit in the United States District Court for the District of New Jersey against Watson Laboratories, Inc. - Florida, Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. (collectively, WLF). The lawsuit alleges that WLF has infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124, and 8,394,407 by filing an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic versions of RAYOS containing 1 mg, 2 mg, and 5 mg of prednisone prior to the expiration of the patents. The subject patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Commencement of the patent infringement lawsuit stays, or bars, FDA approval of WLF's ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or invalid.

Mylan Pharmaceuticals Inc. Announces Settlement Agreement with Shionogi Inc. and Andrx to Resolve Patent Litigation

Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet(R), and is indicated as an adjunct to diet and exercise to lower blood glucose. Under the terms of the settlement agreement, Mylan may launch a generic version of Fortamet(R) on August 1, 2013, or earlier under certain conditions. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Similar Private Companies By Industry

Company Name Region
Therapeutic Discovery Corporation United States
InterGenetics Incorporated United States
Synergos LLC United States
American Distilling & Mfg., Inc. United States
Caraloe Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Andrx Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.